Nexell gets $4.3 million in Baxter deal
This article was originally published in Clinica
Executive Summary
Baxter is to pay $4.3 million for certain assets and liabilities of Nexell Therapeutics' cell processing business, as well as worldwide sales, marketing and distribution rights to related products. It will also get royalties on future product sales. Baxter, which owns around 38% of Nexell, will offer certain Nexell workers positions at Baxter.